SPARC2024-10-012024-12-31 SPARC2024-10-012024-12-31 SPARC2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member SPARC2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member SPARC2024-10-012024-12-31in-bse-fin:OneOperatingExpenses03Member SPARC2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member SPARC2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member SPARC2024-10-012024-12-31in-bse-fin:FourOperatingExpenses03Member SPARC2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532872 SPARC NA Sun Pharma Advanced Research Company Limited Equity 2024-04-01 2025-03-31 2025-02-10 2025-01-31 INR Lakhs Third quarter 18:30:00 19:45:00 2025-02-10 2025-02-10 Not applicable Single segment Pharmaceutical Research and Development 2024-10-01 2024-12-31 Unaudited Standalone 149100000.00 1900000.00 151000000.00 45800000.00 0.00 0.00 264100000.00 27700000.00 27500000.00 583000000.00 948100000.00 -797100000.00 0.00 -797100000.00 0.00 0.00 0.00 0.00 -797100000.00 0.00 0.00 0.00 0.00 -797100000.00 500000.00 -796600000.00 0.00 0.00 324500000.00 1 -2.46 -2.46 0.00 0.00 -2.46 -2.46 1. The above unaudited standalone financial results of Sun Pharma Advanced Research Company Limited (the 'Company') have been prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and have been taken on record by the Board of Directors at its meeting held on February 10, 2025 after being reviewed by the Audit Committee. 2. The Company has incurred cash losses in past quarters and in the current quarter. The Company has a support letter from its promoter group entity basis which its status as Going Concern continues. 3. The Company decided to close the study relating to Parkinson Disease programme (K0706) following results of the PROSEEK trial. The Company is in the process of determining necessary costs for project closure and has made a provision amounting to `1,100 lakhs in the current quarter. 4. The Company has only one reportable business segment namely 'Pharmaceutical Research and Development'. 5.Previous period figures have been regrouped / reclassified, wherever considered necessary. Single segment 2024-04-01 2024-12-31 Unaudited Standalone 445800000.00 17900000.00 463700000.00 174200000.00 0.00 0.00 841300000.00 44000000.00 82800000.00 2163800000.00 3306100000.00 -2842400000.00 0.00 -2842400000.00 0.00 0.00 0.00 0.00 -2842400000.00 0.00 0.00 0.00 0.00 -2842400000.00 1400000.00 -2841000000.00 0.00 0.00 324500000.00 1 -8.76 -8.76 0.00 0.00 -8.76 -8.76 Clinical trial expenses / products development expense 257800000.00 Other expenses 113900000.00 Professional charges 211300000.00 Clinical trial expenses / products development expense 698500000.00 Other expenses 348900000.00 Professional charges 1116400000.00 -500000.00 -1400000.00 0.00 0.00